Jamey P. Weichert
Corporate Officer/Principal presso University of Wisconsin
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Thomas Mackie | M | 69 |
Novelos Therapeutics, Inc.
 Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.
University of Wisconsin
| 4 anni |
| James Caruso | M | 65 | 9 anni | |
| Fred T. Lee | M | - |
University of Wisconsin
| - |
| Stefan Loren | M | 60 | 9 anni | |
| Jarrod Longcor | M | 51 | 8 anni | |
| Warren Porter | M | - |
University of Wisconsin
| - |
| Paul Barford | M | - |
University of Wisconsin
| - |
| David J. Beebe | M | - |
University of Wisconsin
| - |
| Jorge Osorio | M | - |
University of Wisconsin
| - |
| Carl E. Gulbrandsen | M | - |
University of Wisconsin
| - |
| Jon S. Thorson | M | - |
University of Wisconsin
| - |
| Ann M. Murphy | F | - |
University of Wisconsin
| - |
| James A. Thomson | M | 65 |
University of Wisconsin
| 21 anni |
| Charles Pruitt | M | - |
University of Wisconsin
| - |
| Gary Kusnierz | M | - |
University of Wisconsin
| - |
| Michael Carter | M | - |
University of Wisconsin
| - |
| Salvador Carranza | M | - |
University of Wisconsin
| - |
| Darrell Bazzell | M | - |
University of Wisconsin
| - |
| Carolyn Martin | F | - |
University of Wisconsin
| - |
| David Lyle Warnock | M | 66 |
University of Wisconsin
| - |
| Martha Gaines | F | - |
University of Wisconsin
| - |
| Yuri P. Danilov | M | 67 |
University of Wisconsin
| 16 anni |
| Nicholas Tincher | M | - |
University of Wisconsin
| - |
| Jennifer Klippel | F | - |
University of Wisconsin
| - |
| Allan Hanson | M | - |
University of Wisconsin
| - |
| Thomas Holley | M | - |
University of Wisconsin
| - |
| Susan Ottmann | F | 58 |
University of Wisconsin
| 9 anni |
| Héctor Colón | M | 51 |
University of Wisconsin
| - |
| Bin Ran | M | - |
University of Wisconsin
| - |
| Leslie Ann Howard | F | - |
University of Wisconsin
| - |
| Jason Thompson | M | 50 |
University of Wisconsin
| - |
| JoAnne Robbins | M | - |
University of Wisconsin
| - |
| John Zeratsky | M | - |
University of Wisconsin
| 4 anni |
| Thomas Reps | M | - |
University of Wisconsin
| 39 anni |
| Stanley B. Stallworth | M | - |
University of Wisconsin
| - |
| William Reznikoff | M | - |
University of Wisconsin
| 54 anni |
| Yogendra Bharat | M | - |
University of Wisconsin
| - |
| Steven P. Iverson | M | - |
University of Wisconsin
| - |
| Daniel van der Weide | M | - |
University of Wisconsin
| - |
| José M. Delgado | M | - |
University of Wisconsin
| - |
| Bob Atwell | M | 66 |
University of Wisconsin
| - |
| Howard L. Carver | M | 79 |
University of Wisconsin
| - |
| James R. Imhoff | M | 80 |
University of Wisconsin
| - |
| Larry E. Rittenberg | M | 78 |
University of Wisconsin
| 48 anni |
| Mary Ellen Bowers | F | 67 |
University of Wisconsin
| - |
| Steven Pogorzelski | M | 62 |
University of Wisconsin
| - |
| John G. Bollinger | M | 81 |
University of Wisconsin
| - |
| Kay Koplovitz | F | 78 |
University of Wisconsin
| - |
| James Dahlberg | M | - |
University of Wisconsin
| - |
| Frederic E. Mohs | M | 86 |
University of Wisconsin
| - |
| Charles M. Strother | M | 84 |
University of Wisconsin
| - |
| Robert M. Goodman | M | - |
University of Wisconsin
| - |
| Ryan Bennett | M | - |
University of Wisconsin
| - |
| Marshall McGowan Hall | M | - |
University of Wisconsin
| - |
| John D. Folts | M | - |
University of Wisconsin
| - |
| Larry J. Loizzo | M | 69 |
University of Wisconsin
| - |
| Barbara L. Bartell | F | - |
University of Wisconsin
| - |
| James M. Rossmeissl | M | - |
University of Wisconsin
| - |
| Paul A. Spaude | M | - |
University of Wisconsin
| - |
| Hector F. DeLuca | M | - |
University of Wisconsin
| - |
| Margaret Clagett-Dame | M | - |
University of Wisconsin
| 35 anni |
| Christopher Graham | M | - |
University of Wisconsin
| - |
| Max G. Lagally | M | - |
University of Wisconsin
| - |
| Paul M. DeLuca | M | - |
University of Wisconsin
| 53 anni |
| James R. Hayes | M | - |
University of Wisconsin
| - |
| Neil A. Duffie | M | - |
University of Wisconsin
| - |
| Paul Papke | M | - |
University of Wisconsin
| - |
| B. Lynn Allen-Hoffmann | M | - |
University of Wisconsin
| 26 anni |
| David H. Gilbert | M | - |
University of Wisconsin
| - |
| Ruth Brown | F | - |
University of Wisconsin
| - |
| John Garnetti | M | - |
University of Wisconsin
| - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Simon Pedder | M | 63 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 2 anni |
| Kathryn M. McNeil | F | 49 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 2 anni |
| Harry Palmin | M | 54 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 15 anni |
| John Patrick Genn | M | 67 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 5 anni |
| Paul Berns | M | 57 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 3 anni |
| Chad Kolean | M | 59 | 3 anni | |
| George H. Vincent | M | - |
University of Michigan
| 7 anni |
| Joanne M. Protano | F | 55 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 8 anni |
| Avi Rubin | M | - |
University of Michigan
| 9 anni |
| Stein John | M | - |
University of Michigan
| 12 anni |
| James Manuso | M | 75 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | 7 anni |
| Andrew B. Bressler | M | - |
University of Michigan
| 5 anni |
| Monica Rimai | F | - |
University of Michigan
| 7 anni |
| Alex Horvitz | M | - |
University of Michigan
| 5 anni |
| Gerald I. Wilson | M | - |
University of Michigan
| 3 anni |
| Yos Effendi Susanto | M | 73 |
University of Michigan
| 3 anni |
| Marc Robinson | M | 63 |
University of Michigan
| - |
| Mark Alhermizi | M | - |
University of Michigan
| 7 anni |
| Charles Park | M | 57 |
University of Michigan
| 7 anni |
| Izzet Garih | M | 63 |
University of Michigan
| 5 anni |
| Rama Krishna | M | 60 |
University of Michigan
| 3 anni |
| Mike Sayama | M | 69 |
University of Michigan
| 4 anni |
| Anmar Karim Sarafa | M | - |
University of Michigan
| 4 anni |
| Timothy Callahan | M | - |
University of Michigan
| 7 anni |
| Jeffrey Thomas Prince | M | - |
University of Michigan
| 15 anni |
| Michael Krushena | M | - |
University of Michigan
| - |
| David J. Rowland | M | - |
University of Michigan
| 7 anni |
| Elliot Noma | M | - |
University of Michigan
| 4 anni |
| Matthew Gale Longthorne | M | 56 |
University of Michigan
| 4 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Jamey P. Weichert
- Contatti personali
